Preview

Научно-практическая ревматология

Расширенный поиск

Трансплантация аутологичных гемопоэтических стволовых клеток при системной склеродермии

https://doi.org/10.14412/1995-4484-2012-1115

Полный текст:

Об авторах

Р. Т. Алекперов

старший научный сотрудник лаборатории микроциркуляции и воспаления д-р мед. наук


Л. П. Ананьева

заведующая лабораторией микроциркуляции и воспаления профессор д-р мед. наук


Список литературы

1. <div><p>Гусева Н.Г. Системная склеродермия и псевдосклеродермические синдромы. М.: Медицина, 1993.</p><p>Furst D.E., Clements PJ. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol 1997;24(Suppl. 48):53-7.</p><p>Mayes M.D., Lacey J.VJr., Beebe-Dimmer J. et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthr Rheum 2003;48(8):2246-55.</p><p>Storb R. Hematopoietic stem cell transplantation in nonmalignant diseases. J Rheumatol 1997;48(Suppl.):30-5.</p><p>Van Bekkum D.W. Stem cell transplantation in experimental models of autoimmune disease. J Clin Immunol 2000;20:10-6.</p><p>www.clinicaltrials.gov NCT00278525</p><p>Burt R.K., Shah S.J., Dill K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST) an open-label, randomised phase 2 trial. Lancet 2011;378:498-506.</p><p>www.clinicaltrials.gov NCT00114530</p><p>Nash R.A., McSweeney P.A., Crofford L.J. et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007;110:1388-96.</p><p>Loh Y., Oyama Y., Statkute L. et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used? Blood 2007;109:2643-8.</p><p>http//astistrial.com</p><p>Van Laar J.M., Farge D., Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005;64:1515.</p><p>Vonk M.C., Marjanovic Z., van den Hoogen F.H. et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008;67(1):98-104.</p><p>Martini A., Maccario R., Ravelli A. et al. Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. Rheumatology (Oxford) 1999;38(8):773.</p><p>Rosen O., Massenkeil G., Hiepe F. et al. Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamid-induced cardiomyopathy. Bone Marrow Transplant 2001;27(6):657-8.</p><p>Hosing C., Nash R., McSweeney P. et. al. Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States. Biol Blood Marrow Transplant 2011;17(5):674-81.</p><p>Loh Y., Oyama Y., Statkute L. et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 2007;109(6):2643-8.</p><p>Trad S., Amoura Z., Haroche J. et al. Fatal progressive systemic sclerosis following autologous stem cell transplantation and high-dose chemotherapy. Rheumatology (Oxford) 200l;44(7):951-3.</p><p>Launay D., Marjanovic Z., de Bazelaire C. et al. Autologous hematopoietic stem cell transplant in systemic sclerosis: quantitative high resolution computed tomography of the chest scoring. J Rheumatol 2009;36(7):1460-3.</p><p>Yabuuchi H., Matsuo Y., Tsukamoto H. et al. Correlation between pretreatment or follow-up CT findings and therapeutic effect of autologous peripheral blood stem cell transplantation for interstitial pneumonia associated with systemic sclerosis. Eur J Radiol 2011;79(2):e74-9.</p><p>www.clinicaltrials.gov NCT01445821</p><p>Tyndall A. HSCT for systemic sclerosis - swallows and summers. Nat Rev Rheumatol 2011;7(11):624-6.</p><p>Bryan C., Knight C., Black C.M., Silman A.J. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthr Rheum 1999;42:2660-5.</p><p>Gratwohl A., Passweg J., Bocelli-Tyndall C. et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2005;35:869-79.</p><p>Bacigalupo A., Ballen K., Rizzo D. et al. Defining the intensity of conditioning regimens: working definitions. Boil Blood Marrow Transplant 2009;15:1628-33.</p><p>Czirjak L., Nady Z., Aringer M. et al. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007;66:966-9.</p><p>Ra J.C., Kang S.K., Shin I.S. et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med 2011;9:181-91.</p><p>www/clinicaltrials.gov NCT00962923 Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis.</p><p>Silver R.M., Warrick J.H., Kinsella M.B. et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20:838-44.</p><p>Akesson A., Scheja A., Lundin A., Wollheim F.A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthr Rheum 1994;37:729-35.</p><p>Behr J., Bogelmeier C., Beinert T. et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Resp Crit Care Med 1996;154:400-6.</p><p>Steen V.D., Lanz J.K. Jr., Conte C. et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthr Rheum 1994;37:1290-6.</p><p>White B., Moore W.C., Wigley F.M. et al. Cyclo-phosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.</p><p>Giacomelli R., Balentini G., Salsano F. et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29:731-6.</p><p>Griffiths B., Miles S., Moss H. et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002;29:2371-8.</p><p>Abhishek A., Yazdani R., Pearce F. et al. Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide. Clin Rheumatol 2011;30(8):1099-104.</p><p>Tochimoto A., Kawaguchi Y., Hara M. et al. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Mod Rheumatol 2011;21(3):296-301.</p><p>Isik M., Akdogan A., Agit A. et al. Ten-year survival rates of methylprednisolone plus cyclophosphamide followed by mycophenolate mophetyl of azathiopurine for progressive systemic sclerosis patients. Rheumatol Int 2012;32(4):1041.</p><p>Sato S., Fujimoto M., Hasegawa M., Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthr Rheum 2004;50(6):1918-27.</p><p>Sato S., Hasegawa M., Fujimoto M. et al. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunology 2000;165(11):6635-43.</p><p>Matsushita T., Hasegawa M., Yanaba K. et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthr Rheum 2006;54(1):192-201.</p><p>SmithV., van Praet J.T., Vandooren B. et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010;69(1):193-7.</p><p>Lafyatis R., Kissin E., York M. et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthr Rheum 2009;60(2):578-83.</p><p>Daoussis D., Liossis S.N., Tsamandas A.S. et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2009:49(2):271-80.</p><p>Gerbino A.J., Goss C.H., Molitor J.A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008;133(2):455-60.</p><p>Zamora A.C., Wolters PJ., Collard H.R. et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008;102(1):150-5.</p><p>Koutroumpas A., Ziogas A., Alexiou I. et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010;29(10):1167-8.</p><p>Nihtyanova S.I., Brough G.M., Black C.M. et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - a retrospective analysis. Rheumatology (Oxford) 2007;46(3):442-5.</p><p>Derk C.T., Grace E., Shenin M. et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009;48(12):1595-9.</p><p>Liossis S.N., Bounas A., Andonopoulos A.P. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006;45(8):1005-8.</p></div><br />


Для цитирования:


Алекперов Р.Т., Ананьева Л.П. Трансплантация аутологичных гемопоэтических стволовых клеток при системной склеродермии. Научно-практическая ревматология. 2012;50(4):67-72. https://doi.org/10.14412/1995-4484-2012-1115

For citation:


Alekperov R.T., Ananyeva L.P. Autologous hematopoietic stem cell transplantation for systemic scleroderma. Rheumatology Science and Practice. 2012;50(4):67-72. (In Russ.) https://doi.org/10.14412/1995-4484-2012-1115

Просмотров: 694


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)